Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
PM Capital Australian Companies Fund John Whelan and Kevin Bertoli | “During the quarter the Fund initiated a small position in CSL. The business is currently going through a period of reset. Growth plans and the cost base need to be resized, commercial execution sharpened and a permanent Chief Executive Officer appointed. Vifor, the Swiss pharmaceutical company CSL acquired in 2022, faces various challenges and its business might deteriorate faster than expected. The investment case is also evolving. Plasma therapies businesses more generally have elements of both a capital-intensive industrial producing a largely undifferentiated product (immunoglobulin), and a therapeutics business at the leading edge of science. The direction set by the new Chief Executive and, in time, a new Board Chair will be important in determining the company's long-term strategy. CSL, as a stock, is also going through the reset in the minds of the Australian investment community. We do not expect CSL to ever recover the 40-times plus earnings multiple it garnered at its heights in 2020 & 2021. Equally, we do not believe a valuation of 10- or 11- times earnings appropriately reflects a business with high barriers to entry and a product for which there is growing demand.” | NEUTRAL | Q2 2026 Jul 29, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
